{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:01:19Z","timestamp":1791219679355,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"31","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>The European Society of Cardiology guidelines recommend a systematic search for diagnostic clues or \u2018red flags\u2019 (RFs) in patients with hypertrophic cardiomyopathy (HCM) to better tailor disease management. To date, the prevalence and clinical significance of RF associated with HCM phenotypes in different clinical settings are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study cohort comprised 818 patients with a clinical diagnosis of HCM [479 (62%) males, mean age 49 \u00b1 21 years] referred to four European centres. Pre-specified RFs were categorized into one of five domains: (i) family history; (ii) physical examination; (iii) electrocardiography; (iv) echocardiography; and (v) laboratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 318 (39%) patients had a pathogenic or likely pathogenic sarcomere gene variant; 240 (29%) a TTR and GLA variant; 154 (19%) a syndromic cause; and 106 (13%) no identifiable cause. In the overall cohort, 2979 RFs were identified. Of these, 1018 (34%) were identifiable from clinical history and examination alone (generalist setting) and 1961 (66%) by 12-lead electrocardiogram and echocardiography (cardiologist\u2019s office). Non-sarcomeric patients were diagnosed more often aged &amp;lt;20 and after 60 years (476\/500, 95%). Syndromic diseases such as Rasopathies, inherited metabolic disorders, and mitochondrial disorders were diagnosed in neonatal\/early childhood (mean age 3 \u00b1 2 years), whereas patients with Danon disease, Friedreich\u2019s ataxia, Noonan syndrome, and PRKAG2 cardiomyopathy were identified mostly during adolescence (mean age 16 \u00b1 8 years). Non-cardiac RFs identified by clinical history, physical examination, and routine laboratory testing were most frequent in patients with HCM caused by Rasopathies, inherited metabolic disorders, and mitochondrial disorders (48%, 47%, and 57%, respectively). Physical RFs were almost exclusively observed in patients with a definite non-sarcomeric aetiology [348\/350 (99%)]. On the contrary, most RFs associated with geno-positive and geno-negative HCM were derived from electrocardiogram and echocardiography [692\/990 (70%) and 332\/375 (88%), respectively].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Red flags are a common finding in patients presenting with HCM, most commonly non-cardiac in non-sarcomeric aetiology and cardiac in sarcomeric HCM. Over 34% of RF, most relevant to rare HCM phenocopies, can be potentially detected in a generalist setting. Investing in high-touch-low tech, widespread awareness for HCM-related RF may provide substantial advantage in terms of diagnostic yield and appropriate use of resources.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf026","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T11:55:46Z","timestamp":1739188546000},"page":"3082-3094","source":"Crossref","is-referenced-by-count":25,"title":["Hypertrophic cardiomyopathy: prevalence of disease-specific red flags"],"prefix":"10.1093","volume":"46","author":[{"given":"Niccol\u00f2","family":"Maurizi","sequence":"first","affiliation":[{"name":"Service of Cardiology, University Hospital of Lausanne (CHUV) and University of Lausanne (Unil) , Rue du Bugnon 46, BH16, 1011 Lausanne ,","place":["Switzerland"]},{"name":"Cardiomyopathy Unit, Careggi University Hospital , 50121 Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Monda","sequence":"additional","affiliation":[{"name":"Inherited and Rare Cardiovascular Diseases Unit, Department of Translational Medical Sciences, University of Campania \u2018Luigi Vanvitelli\u2019, Monaldi Hospital , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0295-0440","authenticated-orcid":false,"given":"Elena","family":"Biagini","sequence":"additional","affiliation":[{"name":"Cardiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Field","sequence":"additional","affiliation":[{"name":"Centre for Paediatric Inherited and Rare Cardiovascular Disease, Institute of Cardiovascular Science, University College London , London ,","place":["UK"]},{"name":"Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Passantino","sequence":"additional","affiliation":[{"name":"Service of Cardiology, Meyer Children\u2019s Hospital IRCCS , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Dall' Aglio","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi University Hospital , 50121 Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Fumagalli","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi University Hospital , 50121 Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Antiochos","sequence":"additional","affiliation":[{"name":"Service of Cardiology, University Hospital of Lausanne (CHUV) and University of Lausanne (Unil) , Rue du Bugnon 46, BH16, 1011 Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4374-0389","authenticated-orcid":false,"given":"Ioannis","family":"Skalidis","sequence":"additional","affiliation":[{"name":"Service of Cardiology, University Hospital of Lausanne (CHUV) and University of Lausanne (Unil) , Rue du Bugnon 46, BH16, 1011 Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pieroni","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, San Donato Hospital , Arezzo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6394-9948","authenticated-orcid":false,"given":"Alessia","family":"Argir\u00f2","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi University Hospital , 50121 Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Girolami","sequence":"additional","affiliation":[{"name":"Service of Cardiology, Meyer Children\u2019s Hospital IRCCS , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Cecchi","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi University Hospital , 50121 Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Barbey","sequence":"additional","affiliation":[{"name":"Service of Immunology, Lausanne University Hospital , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3083-7333","authenticated-orcid":false,"given":"Pierre","family":"Monney","sequence":"additional","affiliation":[{"name":"Service of Cardiology, University Hospital of Lausanne (CHUV) and University of Lausanne (Unil) , Rue du Bugnon 46, BH16, 1011 Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M","family":"Elliott","sequence":"additional","affiliation":[{"name":"Centre for Heart Muscle Disease, Institute of Cardiological Sciences, University College London and St. Bartholomew\u2019s Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Kaski","sequence":"additional","affiliation":[{"name":"Centre for Paediatric Inherited and Rare Cardiovascular Disease, Institute of Cardiovascular Science, University College London , London ,","place":["UK"]},{"name":"Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8291-9517","authenticated-orcid":false,"given":"Giuseppe","family":"Limongelli","sequence":"additional","affiliation":[{"name":"Inherited and Rare Cardiovascular Diseases Unit, Department of Translational Medical Sciences, University of Campania \u2018Luigi Vanvitelli\u2019, Monaldi Hospital , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi University Hospital , 50121 Florence ,","place":["Italy"]},{"name":"Service of Cardiology, Meyer Children\u2019s Hospital IRCCS , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"2025101323020906400_ehaf026-B1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"2025101323020906400_ehaf026-B2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/jamacardio.2015.0354","article-title":"How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice","volume":"1","author":"Maron","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2025101323020906400_ehaf026-B3","doi-asserted-by":"publisher","first-page":"e00540","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee for service Medicare bene\ufb01ciaries in the United States","volume":"12","author":"Gilstrap","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2025101323020906400_ehaf026-B4","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.mayocp.2021.04.021","article-title":"Early diagnosis and outcome in patients with wild-type transthyretin cardiac amyloidosis","volume":"96","author":"Fumagalli","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2025101323020906400_ehaf026-B5","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2025101323020906400_ehaf026-B6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2025101323020906400_ehaf026-B7","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/eurheartj\/ehy798","article-title":"Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom","volume":"40","author":"Norrish","year":"2019","journal-title":"Eur Heart J"},{"key":"2025101323020906400_ehaf026-B8","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/eurheartj\/ehs397","article-title":"Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis: a position statement from the ESC Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"2025101323020906400_ehaf026-B9","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2025101323020906400_ehaf026-B10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/ejhf.2823","article-title":"Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study","volume":"25","author":"Tini","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2025101323020906400_ehaf026-B11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.hfc.2021.07.004","article-title":"Hypertrophic cardiomyopathy in RASopathies: diagnosis, clinical characteristics, prognostic implications, and management","volume":"18","author":"Lioncino","year":"2022","journal-title":"Heart Fail Clin"},{"key":"2025101323020906400_ehaf026-B12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ijcard.2019.06.073","article-title":"Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy","volume":"299","author":"Limongelli","year":"2020","journal-title":"Int J Cardiol"},{"key":"2025101323020906400_ehaf026-B13","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1111\/echo.14508","article-title":"Echocardiographic features of Fabry cardiomyopathy\u2014comparison with hypertrophy-matched sarcomeric hypertrophic cardiomyopathy","volume":"36","author":"Militaru","year":"2019","journal-title":"Echocardiography"},{"key":"2025101323020906400_ehaf026-B14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/joim.13200","article-title":"Tenosynovial complications identify TTR cardiac amyloidosis among patients with hypertrophic cardiomyopathy phenotype","volume":"289","author":"Cappelli","year":"2021","journal-title":"J Intern Med"},{"key":"2025101323020906400_ehaf026-B15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1001\/jamacardio.2017.2353","article-title":"Intraoperative diagnosis of Anderson-Fabry disease in patients with obstructive hypertrophic cardiomyopathy undergoing surgical myectomy","volume":"2","author":"Cecchi","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2025101323020906400_ehaf026-B16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ijcard.2019.07.051","article-title":"Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy","volume":"300","author":"Maurizi","year":"2020","journal-title":"Int J Cardiol"},{"key":"2025101323020906400_ehaf026-B17","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"2025101323020906400_ehaf026-B18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/anec.12036","article-title":"Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis","volume":"18","author":"Mussinelli","year":"2013","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"2025101323020906400_ehaf026-B19","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jchf.2020.03.007","article-title":"Utility of biomarkers in cardiac amyloidosis","volume":"8","author":"Pregenzer-Wenzler","year":"2020","journal-title":"JACC Hear Fail"},{"key":"2025101323020906400_ehaf026-B20","volume-title":"Essential Medical Statistics","author":"Kirkwood","year":"2003","edition":"2nd ed."},{"key":"2025101323020906400_ehaf026-B21","volume-title":"Categorical Data Analysis","author":"Agresti","year":"2013","edition":"3rd ed."},{"key":"2025101323020906400_ehaf026-B22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.echo.2022.03.012","article-title":"Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: an update from the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography","volume":"35","author":"Nagueh","year":"2022","journal-title":"J Am Soc Echocardiogr"},{"key":"2025101323020906400_ehaf026-B23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.hfc.2018.01.001","article-title":"Clinical and molecular aspects of cardiomyopathies: emerging therapies and clinical trials","volume":"14","author":"Maurizi","year":"2018","journal-title":"Heart Fail Clin"},{"key":"2025101323020906400_ehaf026-B24","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jacc.2016.05.090","article-title":"Genetic screening of Anderson-Fabry disease in probands referred from multispecialty clinics","volume":"68","author":"Favalli","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2025101323020906400_ehaf026-B25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ijcard.2022.03.050","article-title":"Diagnosis and management of rare cardiomyopathies in adult and paediatric patients. A position paper of the Italian Society of Cardiology (SIC) and Italian Society of Paediatric Cardiology (SICP)","volume":"357","author":"Limongelli","year":"2022","journal-title":"Int J Cardiol"},{"key":"2025101323020906400_ehaf026-B26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.118.038846","article-title":"Yield of clinical screening for hypertrophic cardiomyopathy in child first-degree relatives","volume":"140","author":"Norrish","year":"2019","journal-title":"Circulation"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/31\/3082\/61821014\/ehaf026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/31\/3082\/61821014\/ehaf026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T03:02:46Z","timestamp":1760410966000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/31\/3082\/8006613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":26,"journal-issue":{"issue":"31","published-online":{"date-parts":[[2025,2,10]]},"published-print":{"date-parts":[[2025,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf026","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,14]]},"published":{"date-parts":[[2025,2,10]]}}}